Thomas Sciascia has sold TRVI and made no open-market buys since May 2024
Chief Scientific Officer at Trevi Therapeutics, Inc.
SEC CIK 0001229946 · Filings on SEC.gov ↗
$0Bought
$272KSold
NoneLast buy
Every filing
3 filings since May 2024, newest first
Filings come from SEC EDGAR. Not investment advice.